Post-transplant lymphoproliferative disorder (PTLD) is a well-recognized complication after solid organ and hematopoietic SCTs (HSCTs). The majority are of B-cell origin and EBV related. 1 Most of the T-cell PTLD cases have been described as occurring after solid organ transplantations; 2 T-cell PTLD cases following HSCT are exceedingly rare. There are only three reported cases of T-cell PTLD following allogeneic HSCT 3 and four cases following autologous HSCT. [4] [5] [6] [7] Here we report a case of T-cell PTLD after allogeneic-PBSC transplantation (allo-PBSCT) in a patient with chronic idiopathic myelofibrosis (CIMF).
A 44-year-old Japanese woman with anemia and fever was diagnosed with CIMF in November 2006. At the time of her diagnosis, her WBC count was 900/ml, Hb 6.9 g/dl, plt count 39 000/ml with no morphologically abnormal cells in her peripheral blood, and an abdominal CT scan showed mild splenomegaly without hepatomegaly, lymphadenopathy or liver tumor. A specimen of her biopsied BM showed diffuse fibrosis and a decreased number of hematopoietic cells. No abnormal cell proliferation was observed. In December 2006, she underwent allo-PBSCT from an HLA-identical brother. Neutrophil engraftment was achieved on day 17 after transplant, and BM analysis showed full hematological recovery with 100% donortype chimerism assessed by Y chromosome-based FISH analysis. As grade II acute GVHD involving the skin and subsequently an extensive type of chronic GVHD (cGVHD) developed; continued immunosuppressive therapy with cyclosporine and prednisolone was required for several months after the transplant. At 5 months after transplant, a liver tumor, 2 cm in diameter, was detected by an abdominal CT scan. Although PTLD was raised as a differential diagnosis, biopsied liver tissue was inadequate for pathological examination. Immunosuppressive therapy was reduced, resulting in a decrease in liver tumor size to 1.6 cm in 2 months. However, a subsequent flare-up of cGVHD required more intensive immunosuppressive therapy, and the liver tumor's diameter increased twice in size. A liver tumor biopsy performed at this time showed a diffuse proliferation of atypical lymphoid cells (Figure 1a) . Immunohistochemically, these tumor cells were positive for LCA, CD3, CD7 and CD8, and negative for CD4, CD5, CD34, CD79a, MPO, CD30, CD56 and TdT (Figure 1b ). These pathological findings are compatible with peripheral T-cell lymphoma-unspecified ( Figure 1c ). EBV infection was not detected by in situ hybridization. Y chromosomebased FISH analysis revealed the tumor cells were of recipient origin. She suffered from fever, pancytopenia and decreased liver function, and was hospitalized for further therapy in November 2007. BM examination showed infiltration of 4% abnormal lymphoid cells and the proliferation of macrophage with hemophagocytosis, with no sign of CIMF recurrence. Chromosome analysis of the BM cells showed 44, X, der(X)t(X;7)(q13;q11.2), add(2)(q21), add(4)(p11), add(4)(p16), der(9;17)(q10;q10), À10, À13, add(15)(p11), þ mar [2/20 ]. An abdominal CT scan showed that the liver tumor grew rapidly to a size of 12 Â 6 cm 2 ( Figure 1d ). Serological tests for HIV, HBV, HCV and HTLV-1 were negative, and the EBV VCA IgG was positive but negative for IgM. Analyses by real-time PCR were negative for human herpesvirus-6, VZV, CMV and EBV in her peripheral blood. She was diagnosed with T-cell PTLD with lymphoma-associated hemophagocytic syndrome. CHOP therapy was started, but the disease progressed within 2 weeks after this. She underwent urgent unrelated cord blood transplantation (UCBT) from an HLA two antigen-mismatched donor. Her post-transplant course was complicated by sepsis, renal failure and respiratory failure. She died on day 6 after UCBT. An autopsy was not performed.
To our knowledge, there have been only four cases of T-cell PTLD following allo-SCT, including our case (Table 1) . Time to T-cell PTLD diagnosis ranges from 2 to 43 months after a transplant. Although the type of PTLD was not consistent, ranging from precursor to peripheral T-cell neoplasms, none of them were associated with EBV infection. Our case was negative for EBV, and the type was peripheral T-cell lymphoma-unspecified.
There have been a few reports describing myelofibrosis in association with T-cell lymphoma. 8 In these cases, PDGF and tumor growth factor b, which may have been secreted by neoplastic T lymphocytes, had an important role in the development of myelofibrosis. In our case, there was no clinical evidence of T-cell lymphoma at the time of CIMF diagnosis, and no sign of myelofibrosis recurrence at the onset of T-cell lymphoma. Thus, the development of T-cell lymphoma in this case was considered to be independent of the CIMF.
All three patients reported as having T-cell PTLD following allo-SCT had severe GVHD and received a heavy dose of immunosuppressive agents, suggesting some viral agents in an immunosuppressed state may have an important role in the development of T-cell PTLD. However, we were unable to find any evidence of viral infection and reactivation in our case and previously reported cases. It has been reported that only 15 of 76 cases of T-cell PTLD after solid organ transplantation were EBV positive, 9 and any other viral involvement has not been clearly demonstrated. These findings suggest that not only viral infection but also other factors, such as chronic antigenic stimulation, impaired immunoregulation and genetic factors, may be associated with the development of T-cell PTLD. 10 The outcomes of reported T-cell PTLD so far are poor. All patients died because of the progression of the disease. In our patient, a transient response was observed by reducing immunosuppression, suggesting a graft-versuslymphoma effect, which was necessitated to increase the immunosuppression. Standard cytotoxic chemotherapy led to a poor response in our patient, similar to the other cases previously described. More intensive chemotherapy, donor lymphocyte infusion or second HSCT should be considered at an early stage of the disease.
In conclusion, T-cell PTLD rarely occurs after allo-HSCT. Further research, however, is needed to fully characterize the clinicopathological features of this condition and to investigate the optimal therapy.
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